Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2022.53285
Abstract: Importance High-grade gliomas (HGGs) constitute the most common and aggressive primary brain tumor, with 5-year survival rates of 30.9% for grade 3 gliomas and 6.6% for grade 4 gliomas. The add-on efficacy of interferon alfa… read more here.
Keywords: grade gliomas; patients newly; newly diagnosed; alfa ... See more keywords
Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26644
Abstract: Patients with chronic kidney disease (CKD) develop anemia largely because of inappropriately low erythropoietin (EPO) production and insufficient iron available to erythroid precursors. In four phase 3, randomized, open‐label, clinical trials in dialysis‐dependent and non–dialysis‐dependent… read more here.
Keywords: anemia associated; chronic kidney; alfa; kidney disease ... See more keywords
SEBELIPASE ALFA IN CHILDREN AND ADULTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY: FINAL RESULTS OF THE ARISE STUDY.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of hepatology"
DOI: 10.1016/j.jhep.2021.10.026
Abstract: BACKGROUND & AIMS Children and adults with lysosomal acid lipase deficiency (LAL-D) experience cirrhosis and dyslipidemia from lysosomal accumulation of cholesteryl esters and triglycerides. Sebelipase alfa enzyme replacement therapy is indicated for individuals with LAL-D.… read more here.
Keywords: open label; sebelipase alfa; lysosomal acid; alfa ... See more keywords
The budget impact of enzyme replacement therapy in type 1 Gaucher disease in the United States
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2082200
Abstract: Abstract Aim Gaucher disease (GD) is a rare autosomal recessive condition. Type 1 GD (GD1) is the most prevalent form of GD in Western countries; enzyme replacement therapy (ERT) is a treatment option for patients… read more here.
Keywords: alfa; velaglucerase alfa; budget impact;
Preprint Highlight: ALIBY: ALFA nanobody-based toolkit for imaging and biochemistry in yeast.
Sign Up to like & getrecommendations! Published in 2022 at "Molecular biology of the cell"
DOI: 10.1091/mbc.p22-10-1004
Abstract: Many commonly used protein epitope tags are optimized for one or a few biological applications. The recently developed ALFA tag performs well across a broad range of cell biological applications including localization, biochemical, and functional… read more here.
Keywords: highlight aliby; alfa nanobody; preprint highlight; alfa ... See more keywords
Novel Long-Acting Ropeginterferon Alfa-2b: Pharmacokinetics, Pharmacodynamics, and Safety in a Phase I Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15176
Abstract: AIM Ropeginterferon alfa-2b is a novel, long-acting pegylated interferon alfa-2b. We aimed to evaluate its safety, pharmacokinetics (PK) and pharmacodynamics (PD). METHODS Thirty-six subjects received single subcutaneous injection of ropeginterferon alfa-2b at doses ranging 24-270… read more here.
Keywords: safety; pegylated ifn; ropeginterferon alfa; ifn alfa ... See more keywords
Preclinical safety and efficacy of andexanet alfa in animal models
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thrombosis and Haemostasis"
DOI: 10.1111/jth.13768
Abstract: Essentials There is currently no approved reversal agent for factor Xa (FXa) inhibitors Andexanet alfa has been developed to reverse the anticoagulant effects of FXa inhibitors Andexanet reduced blood loss and anticoagulation markers in rivaroxaban‐anticoagulated… read more here.
Keywords: alfa animal; efficacy andexanet; safety efficacy; preclinical safety ... See more keywords
Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004601
Abstract: Purpose Bintrafusp alfa is a bifunctional agent consisting of an anti-human PD-L1 antibody linked to two TGFβRII. It is designed to act both as a checkpoint inhibitor and to ‘trap’ TGFβ in the tumor microenvironment.… read more here.
Keywords: alfa; hpv associated; peripheral immunome; patients hpv ... See more keywords
Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-005267
Abstract: Background Cluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and can lead to protumor conditions. This Phase 1 study (NCT03954704) evaluated the safety, pharmacokinetics, pharmacodynamics, and… read more here.
Keywords: patients advanced; alfa; dalutrafusp alfa; tgf ... See more keywords
Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Applied Thrombosis/Hemostasis"
DOI: 10.1177/10760296221110568
Abstract: Purpose: To assess costs and healthcare resource utilization (HCRU) associated with the use of idarucizumab for the reversal of dabigatran and andexanet alfa for the reversal of direct oral Factor Xa inhibitors. Methods: This retrospective… read more here.
Keywords: costs healthcare; alfa; reversal; healthcare resource ... See more keywords
Successful of Immune Tolerance Induction (R-ITI) with Simoctocog Alfa (rhFVIII) in Hemophilia a Patients and High-Titer Inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-114615
Abstract: Backgroud: The appearance of inhibitors (INH) is the most serious complication in hemophilia A (HA) patients. The primary objective is their eradication. Usually the primary ITI was performed with the same concentrate causing INH development,… read more here.
Keywords: inhibitor; treatment; alfa; simoctocog alfa ... See more keywords